,i  #aacth ,,congress  #ast ,session    
,h4 ,r4 #ahcj  ,,in ,,the ,,house ,,of  
,,representatives  ,may #f1 #bjac ,mrs4 
,capito 7for herself1 ,ms4 ,castor of   
,florida1 ,ms4 ,bass1 ,mrs4 ,blackburn1 
,mr4 ,latham1 ,mr4 ,loebsack1 ,mr4      
,markey1 ,ms4 ,moore1 and ,mr4 ,tiberi7 
introduced the following bill2 which was
 referred to the ,committee on ,energy  
and ,commerce  ,a ,,bill  ,to provide   
for the establishment of a ,commission  
to ,accelerate the ,end of ,breast      
,cancer4  #a4 ,short title ,this ,act   
may be cited as the ,accelerating the   
,end of ,breast ,cancer ,act of #bjac4  
#b4 ,table of contents ,the table of    
contents of this ,act is as follows3    
,sec4 #a4 ,short title4 ,sec4 #b4 ,table
 of contents4 ,sec4 #c4 ,findings4 ,sec4
 #d4 ,establishment4 ,sec4 #e4 ,mission2
 duties4 ,sec4 #f4 ,membership4 ,sec4   
#g4 ,chairperson and commissioners4     
,sec4 #h4 ,coordination and             
nonduplication4 ,sec4 #i4 ,evaluation of
 the commission4 ,sec4 #aj4             

,termination4  #c4 ,findings ,the       
,congress finds the following3  7#a7 ,in
 the ,united ,states1 the chance of a   
woman developing breast cancer during   
her lifetime has increased from #a in   
#aa in #aige to #a in #h today4  7#b7   
,worldwide1 breast cancer is the most   
frequently diagnosed cancer in women    
with #a4c million cases each year and   
the leading cause of cancer death with  
more than #ejj1jjj women dying from the 
disease in #bjaj4  7#c7 ,more than #ij  
percent of deaths from breast cancer are
 caused by metastasis1 when breast      
cancer has spread to other organs or    
bone4  7#d7 ,the ,national ,cancer      
,institute estimated that breast cancer 
care in the ,united ,states cost #af4e  
billion in #bjji and cost the ,nation   
#ab4a billion in lost productivity4     
7#e7 ,very little has improved in terms 
of breast cancer incidence1 morbidity1  
and mortality rates over the past #dj   
years4  #d4 ,establishment ,the         
,president shall establish a commission 

to be known as the ,commission to       
,accelerate the ,end of ,breast ,cancer 
7in this ,act referred to as the the    
,commission74  #e4 ,mission2 duties  7a7
 ,mission ,the mission of the           
,commission shall be to help end breast 
cancer by ,january #a1 #bjbj4  7b7      
,duties ,the ,commission shall--  7#a7  
identify opportunities and ideas within 
government and the private sector that  
are key components in achieving the end 
of breast cancer and which have been    
overlooked1 yet are ripe for            
collaboration and investment1 and  7#b7 
recommend projects to leverage such     
opportunities and ideas in the areas    
of--  7,a7 the primary prevention of    
breast cancer2 and  7,b7 the causes and 
prevention of breast cancer metastasis4 
7c7 ,means ,in carrying out the duties  
described in subsection 7b71 the        
,commission shall--  7#a7 identify      
revolutionary opportunities and ideas in
 fundamental and applied sciences and   
epidemiology with a focus on ending     

breast cancer2  7#b7 identify timely    
opportunities and scientific discoveries
 which can be turned into real world    
strategies to prevent breast cancer and 
prevent breast cancer metastasis and    
deaths2  7#c7 promote ideas that are    
intellectually compelling1 innovative1  
and imaginative2  7#d7 accelerate       
potential transformational scientific   
advances--  7,a7 not being prioritized  
within the ,federal ,government1 but    
which can help to achieve the mission   
described in subsection 7a72 and  7,b7  
unlikely to be achieved by the private  
sector due to technical and financial   
uncertainty2  7#e7 identify promising1  
underdeveloped areas of research that   
would benefit from a cluster of         
government1 industry1 and academia      
forming innovation communities to       
rapidly advance knowledge into practice1
 while creating new opportunities for   
job creation and advancement2  7#f7     
identify opportunities for              
transdisciplinary cross-cutting         

collaborations2 and  7#g7 identify      
opportunities for seed grants to        
leverage identified opportunities and   
ideas4  7d7 ,strategic vision ,not later
 than #f months after the appointment of
 the initial members of the ,commission1
 the ,commission shall submit to the    
,president and the relevant authorizing 
and appropriations committees of the    
,congress a description of the          
,commission's strategic vision for      
making progress in achieving the mission
 described in subsection 7a7 by ,january
 #a1 #bjbj4  7e7 ,annual reports ,the   
,commission shall submit an annual      
report to the ,president1 the ,congress1
 and the public describing the          
,commission's activities under this     
section1 including its progress in      
achieving the mission described in      
subsection 7a74  #f4 ,membership  7a7   
,number2 appointment ,the ,commission   
shall be composed of not more than #aj  
members1 of which--  7#a7 not more than 
#h shall be appointed by the ,president2

  7#b7 #a shall be appointed by the     
,speaker of the ,house of               
,representatives2 and  7#c7 #a shall be 
appointed by the majority leader of the 
,senate4  7b7 ,composition  7#a7 ,in    
general ,each member of the ,commission 
shall be appointed to represent one of  
the following #c categories3  7,a7      
,representatives of varied disciplines  
within the biomedical research field4   
7,b7 ,representatives of varied         
disciplines outside of the biomedical   
research field4  7,c7 ,educated patient 
advocates1 meaning individuals who--    
7i7 represent a patient-led1            
patient-centered organization with a    
patient constituency2  7ii7 have been   
personally affected by breast cancer2   
and  7iii7 are trained1 knowledgeable1  
and prepared to participate in the      
decisionmaking process of science and   
medicine4  7#b7 ,representation of      
membership categories ,of the members of
 the ,commission--  7,a7 at least #a but
 not more than #c shall be appointed to 

represent the category described in     
paragraph 7#a77;,a72  7,b7 at least #a  
but not more than #c shall be appointed 
to represent the category described in  
paragraph 7#a77;,b72 and  7,c7 at least 
#b but not more than #d shall be        
appointed to represent the category     
described in paragraph 7#a77;,c74  7c7  
,initial members ,the initial members of
 the ,commission shall be appointed not 
later than #fj days after the date of   
the enactment of this ,act4  7d7 ,terms 
7#a7 ,in general ,each member of the    
,commission shall be appointed for a    
term of #c years and may be reappointed4
  7#b7 ,vacancies ,any member of the    
,commission appointed to fill a vacancy 
occurring before the expiration of the  
term for which the member's predecessor 
was appointed shall be appointed only   
for the remainder of that term4 ,a      
member may serve after the expiration of
 that member's term until a successor   
has taken office4 ,a vacancy in the     
,commission shall be filled in the      

manner in which the original appointment
 was made4  7e7 ,quorum ,three members  
of the ,commission shall constitute a   
quorum4  #g4 ,chairperson and           
commissioners  7a7 ,chairperson  7#a7   
,designation ,of the members of the     
,commission appointed under section     
#f7;a71 the ,president shall at the time
 of appointment1 designate one to serve 
as ,chairperson of the ,commission4     
7#b7 ,qualifications ,the ,chairperson  
shall be an individual who1 by reason of
 professional background and experience1
 is especially qualified to manage areas
 of study pertaining to ending breast   
cancer by ,january #a1 #bjbj4  7#c7     
,responsibilities ,the responsibilities 
of the ,chairperson shall include--     
7,a7 approving all new study projects   
and areas of study of the ,commission   
based on innovation1 impact1 and        
scientific and technical merit2  7,b7   
developing criteria 7including          
milestones7 for assessing1 and          
overseeing assessment of1 the success of

 the study projects and areas of study  
of the ,commission2  7,c7 identifying   
opportunities for seed grants and other 
funding through awards1 prizes1 grants1 
and contracts to achieve the mission    
described in section #e7;a72 and  7,d7  
terminating study projects and areas of 
study of the ,commission that are not   
achieving the mission described in      
section #e7;a74  7b7 ,commissioners     
7#a7 ,in general ,the ,chairperson of   
the ,commission may appoint members of  
the ,commission to oversee one or more  
areas of study of the ,commission4  7#b7
 ,responsibilities ,a member appointed  
under paragraph 7#a7 shall1 with respect
 to one or more areas of study1 be      
responsible for--  7,a7 recommending    
novel proposals1 projects1 and          
collaborations based on scientific and  
technical merit to achieve the mission  
described in section #e7;a7 with a focus
 on strategies for the primary          
prevention of breast cancer1 and methods
 to prevent breast cancer metastasis2   

7,b7 identifying ideas and opportunities
 to achieve the mission described in    
section #e7;a7 that are intellectually  
compelling1 innovative1 and imaginative1
 including such ideas and opportunities 
not being prioritized for breast cancer 
relevance within ,federal agencies or   
programs or the private sector2  7,c7   
working with other relevant ,federal    
agencies to identify areas of concurrent
 interests in order to maximize ,federal
 investment and stimulate collaborative 
projects2  7,d7 identifying             
opportunities for transdisciplinary1    
cross-cutting collaborations2 and  7,e7 
monitoring the progress of study        
projects and areas of study and         
recommending restructure or termination4
  #h4 ,coordination and nonduplication  
,to the maximum extent practicable1 the 
,commission shall ensure that the       
activities of the ,commission are       
coordinated with1 and do not duplicate  
the efforts of1 programs and            
laboratories of other government        

agencies4  #i4 ,evaluation of the       
commission  7a7 ,in general ,the        
,president shall seek to enter into an  
agreement with the ,institute of        
,medicine of the ,national ,academy of  
,sciences under which the ,institute1   
after the ,commission has been in       
operation for #c years1 completes an    
evaluation of how well the ,commission  
is making progress towards achieving the
 mission described in section #e7;a74   
7b7 ,inclusions ,the evaluation under   
subsection 7a7 shall include--  7#a7 a  
recommendation on whether the           
,commission should be continued or      
terminated2 and  7#b7 a description of  
lessons learned from operation of the   
,commission4  7c7 ,availability ,on     
completion of the evaluation under      
subsection 7a71 the ,commission shall   
make the evaluation available to the    
,congress and the public4  #aj4         
,termination ,the ,commission shall     
terminate on ,june #a1 #bjbj4